Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 4/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 13/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | CTSA | P10619 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4158613 | 0.87 | PTGER1 (0.51) | PTGER1CYP2C9CYP3A4CYP2C19SCN9A | |
| SCHEMBL4147273 | 0.86 | PTGER1 (0.63) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL5619610 | 0.85 | PTGER1 (0.72) | PTGER1CYP2C9CYP3A4CYP2C19MRGPRX4 | |
| SCHEMBL4154715 | 0.85 | PTGER1 (0.46) | PTGER1CYP2C9CYP3A4CYP2C19SCN9A | |
| SCHEMBL4163535 | 0.84 | PTGER1 (0.61) | PTGER1CYP2C9CYP3A4CYP2C19SCN9A | |
| SCHEMBL4926588 | 0.83 | PTGER1 (0.69) | PTGER1CYP2C9CYP3A4CYP2C19MRGPRX4 | |
| SCHEMBL5620302 | 0.83 | PTGER1 (0.64) | PTGER1CYP2C9CYP3A4CYP2C19MRGPRX4 | |
| SCHEMBL4168573 | 0.82 | PTGER1 (0.66) | PTGER1CYP2C9CYP3A4CYP2C19MRGPRX4 | |
| SCHEMBL4167232 | 0.82 | PTGER1 (0.63) | PTGER1CYP2C9CYP3A4CYP2C19MRGPRX4 | |
| SCHEMBL4162393 | 0.82 | PTGER1 (0.64) | PTGER1CYP2C9CYP3A4CYP2C19SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| EP-1670763-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005037793-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | C1R, CYP1B1, ADORA2B | PTGER1 246/4885CYP2C9 5/4885CYP3A4 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.